AstraZeneca PLC — Director's Dealing 2017

Dec 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ALBIREO PHARMA, INC. (ALBO)
CIK: 0001322505
Period of Report: 2017-12-01

Reporting Person: ASTRAZENECA PLC (10% Owner)
Reporting Person: ASTRAZENECA AB (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-01	Common Stock, $0.01 par value per share	S	500000	$21.40	Disposed	508141	Indirect

Footnotes

F1: All of these securities are owned by AstraZeneca AB, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to indirectly beneficially own the shares held by AstraZeneca AB, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any. The principal business address of AstraZeneca AB is SE-151, 85 Sodertalje, Sweden.